Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer

Shanghai Pulmonary Hospital, Shanghai, China

Status and phase: Enrolling; Phase 2

Conditions: Lung Neoplasms; Thoracic Neoplasms; Lung Diseases; Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Treatments: Drug: Teniposide administration

Study type: Interventional

Funder types: Other

Identifiers

NCT06758700

VM26-201

ChiCTR2400094090 (Other Identifier)

Details and patient eligibility

About

The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2/MYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2/MYC and the efficacy of teniposide.

Enrollment: 15 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. extensive stage small cell lung cancer
2. Progression after receiving at least one chemotherapy drug treatment in the past;
3. ECOG score 0-1
4. c-Myc-driven
5. Expected survival period ≥3 months
6. Age: 18-75 years old;
7. The informed consent form complies with the ICH-GCP principles.

Exclusion criteria

1. No measurable lesions
2. Other severe and persistent diseases or organ system dysfunction;
3. Women planning pregnancy or men planning family planning;
4. Women who are pregnant or breastfeeding;
5. Those who cannot follow the research protocol provided by the investigator.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

15 participants in 1 patient group

Teniposide group

Other group

Description:

Teniposide administration

Treatment:

Drug: Teniposide administration